Business Wire

Neustar: New Ponemon Institute Report highlights value of threat data feeds in improving organisations’ security posture

Share

Threat data feeds can help organisations strengthen their cybersecurity posture, according to a new report from Ponemon Institute, the pre-eminent research centre dedicated to privacy, data protection and information security policy. Neustar Inc., a global information services and technology company and leader in identity resolution, sponsored the independently conducted study on the state of threat feed effectiveness in the United States and the United Kingdom.

As cyberthreats proliferate, many organisations are using threat feeds with insights from domain name system (DNS) data to help IT security teams better understand threats and block malicious activity. A large majority (79%) of the more than 1,000 security professionals participating in the Ponemon study said threat data feeds were essential to their organisation’s ability to achieve a strong cybersecurity posture, and more than half (55%) rate the quality of their threat feeds’ ability to pinpoint cyberthreats as very high.

Study participants said threat data feeds offer a number of benefits: they add unique data to better inform security (71%), increase preventive blocking to ensure a better defence (63%), reduce the mean time to detect and remediate an attack (55%), and reduce the time spent researching false positives (51%).

However, more than half (56%) of respondents also said threat feeds deliver data that is often too voluminous and/or complex to provide timely and actionable intelligence.

Neustar’s UltraThreat Feeds service addresses these issues by drawing on proprietary data derived from the company’s expansive authoritative and recursive DNS services, DDoS mitigation solutions, OneID system and IP geolocation data. This service, which processes the data and outputs the observations and key insights, has been designed by Neustar’s renowned DNS experts, as well as leading academic researchers. UltraThreat Feeds data, provided as either near real-time threat data feeds or via API calls (JSON format), enable organisations to detect potential threats and identify and stop bad traffic, both inbound and outbound.

“Facing an increase in the volume, sophistication and diversity of threats, enterprises are investing significant resources into threat intelligence solutions to bolster their cyber defences,” said Michael Kaczmarek, senior vice president at Neustar. “Solutions that deliver real-time information on active threats, like Neustar’s UltraThreat Feeds service, can quickly deliver ROI across many layers of an organisation’s defence by improving the performance of network and application security tools – such as SIEMs, TIPs, Next Gen Firewalls, IPS/IDS, WAFs, and DNS Firewalls – which require threat data to effectively detect and block malicious actors.”

Each of the organisations surveyed by Ponemon faced an average of 28 cyberattacks in the past two years. On average, respondents said 38% of these cyberattacks were not stopped because security teams lacked timely and actionable data from their data feeds. Respondents also reported that half (50%) of all attacks can be stopped using timely and actionable intelligence from their threat feeds.

“The deep, rich threat data delivered by Neustar’s UltraThreat Feeds service empowers users to identify indicators of compromise or malicious activity in near real time and act accordingly to limit or even prevent attacks,” added Kaczmarek.

The Ponemon report is based on survey responses from 1,025 IT security practitioners (70% of whom were at or above the supervisory level) in the U.S. and the U.K. whose organisations use threat data in their cybersecurity programmes or infrastructure. The most-represented industry was financial services (18% of respondents), followed by industrial and manufacturing (12%), retail (11%), public sector (11%), and health and pharmaceuticals (9%). Just over half of the participants were from organisations with a global headcount of more than 5,000 employees. The surveys were carried out in November 2020.

To access the full report, go to https://www.home.neustar/resources/whitepapers/state-of-threat-feed-effectiveness.

For more information about Neustar’s UltraThreat Feeds, visit https://www.home.neustar/security-intelligence/ultrathreat-feeds. To learn more about Neustar’s full suite of security solutions, visit https://www.home.neustar/security-solutions.

-ENDS-

About Neustar
Neustar is an information services and technology company and a leader in identity resolution providing the data and technology that enable trusted connections between companies and people at the moments that matter most. Neustar offers industry-leading solutions in marketing, risk, communications and security that responsibly connect data on people, devices and locations, continuously corroborated through billions of transactions. Neustar serves more than 8,000 clients worldwide, including 60 of the Fortune 100. Learn how your company can benefit from the power of trusted connections here: https://www.home.neustar.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Neustar Media Contact
Jenny Morris
Hotwire for Neustar
+44 (0)7393465529
neustaruk@hotwireglobal.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Microba Announces Landmark GI Study Results From Over 4,600 Patients15.5.2025 05:12:00 EEST | Press release

Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often go undetected by conventional testing. In over 70% of cases, the test revealed findings, such as abnormalities in gut bacteria, signs of infection, markers of inflammation or insufficiency that could inform targeted treatment strategies. Further, two-thirds of MetaXplore patients in a separate study of follow up survey results reported improvement of symptoms after their care was guided by the test results. This press release features multimedia. View the full release here: https://www.businesswire.

Bloomstreet Enters into Strategic Partnership Agreement with Google Israel for Market Expansion in Japan15.5.2025 05:00:00 EEST | Press release

Bloomstreet Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Junichi Takayama; hereinafter “Bloomstreet”), a company that supports overseas enterprises entering the Japanese market, is pleased to announce a strategic partnership agreement with Google Israel Ltd. (Headquarters: Tel Aviv District; Country Manager: Barak Regev; hereinafter “Google Israel”). This partnership aims to support Israeli companies that operate globally with Google Ads and are seeking to expand into the Japanese market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514387485/en/ How do Bloomstreet and Google Israel collaborate? The partnership between Bloomstreet and Google Israel is designed to support Israeli companies seeking to expand into the Japanese market by optimizing their website UI/UX, thereby enhancing the effectiveness of their Google Ads campaigns. Background of the Partnership Known as a "Start-up Nation," Israel is home to many

Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience15.5.2025 04:11:00 EEST | Press release

Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company’s broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called “zombie” cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and Lauren Donovan, PhD, and co-authored by Rubedo team members, including Chief Scientific Officer Marco Quarta, PhD, and Chief Technology Officer Alex Laslavic, was published in the May 14th edition of Nat

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 115.5.2025 00:03:00 EEST | Press release

Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes NT1. Results demonstrated significant improvement in objective and subjective measures of excessive daytime sleepiness (EDS), reductions in cataplexy events and clinically meaningful improvements in disease severity and quality of life across all doses tested compared to placebo through eight weeks of treatment. NT1 is a severe, chronic neurological condition caused by a significant loss of orexin-producing neurons, resulting in low levels of orexin leading to EDS, cataplexy (sudden loss of muscle tone), cognitive symptoms, disrupted nighttime sleep, hallucinations that occur as one falls asleep or wakes up and sleep paralysis.T

BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation14.5.2025 23:05:00 EEST | Press release

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four selected for oral presentations, featuring data from its best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib) and its investigational pipeline assets – a next-generation BCL2 inhibitor, sonrotoclax, and BTK protein degrader, BGB-16673. These data reflect BeiGene’s vision to redefine standards of care in hematology through next-generation science and patient-focused innovation. “With three cornerstone hematology assets – BRUKINSA, sonrotoclax and BGB-16673 – we are advancing a potentially best-in-class portfolio in B-cell malignancies,” said Lai Wang, Ph.D. Global Head of R&D. “At EHA 2025, we’ll share 31 accepted ab

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye